Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 2
2004 2
2005 4
2006 2
2007 3
2008 2
2009 5
2010 8
2011 14
2012 10
2013 5
2014 10
2015 11
2016 9
2017 4
2018 4
2021 0
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 26743341

79 results
Results by year
Filters applied: . Clear all
Page 1
Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid Malignancies.
Shinozuka K, Tang H, Jones RB, Li D, Nieto Y. Shinozuka K, et al. Biol Blood Marrow Transplant. 2016 May;22(5):843-9. doi: 10.1016/j.bbmt.2015.12.022. Epub 2015 Dec 29. Biol Blood Marrow Transplant. 2016. PMID: 26743341 Free PMC article.
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.
Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Nieto Y, et al. Cancer. 2016 Sep 1;122(17):2680-8. doi: 10.1002/cncr.30100. Epub 2016 May 20. Cancer. 2016. PMID: 27203405 Free PMC article.
Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.
Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. Nieto Y, et al. Biol Blood Marrow Transplant. 2013 Mar;19(3):410-7. doi: 10.1016/j.bbmt.2012.10.029. Epub 2012 Nov 2. Biol Blood Marrow Transplant. 2013. PMID: 23128322 Free PMC article. Clinical Trial.
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS. Nieto Y, et al. Biol Blood Marrow Transplant. 2018 Aug;24(8):1602-1609. doi: 10.1016/j.bbmt.2018.02.020. Epub 2018 Mar 2. Biol Blood Marrow Transplant. 2018. PMID: 29501779 Free article. Clinical Trial.
The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.
Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS. Valdez BC, et al. Leuk Lymphoma. 2017 Nov;58(11):2705-2716. doi: 10.1080/10428194.2017.1306647. Epub 2017 Apr 10. Leuk Lymphoma. 2017. PMID: 28394191 Free PMC article.
Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.
Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D. Okazaki T, et al. Clin Cancer Res. 2010 Jan 1;16(1):320-9. doi: 10.1158/1078-0432.CCR-09-1555. Epub 2009 Dec 22. Clin Cancer Res. 2010. PMID: 20028759 Free PMC article.
Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.
Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, Doodeman VD, Smits PH, Vincent A, Huitema AD, Beijnen JH, Schellens JH. Joerger M, et al. Cancer. 2012 May 1;118(9):2466-75. doi: 10.1002/cncr.26562. Epub 2011 Sep 28. Cancer. 2012. PMID: 22031394 Free article. Clinical Trial.
DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer.
Dong X, Li Y, Hess KR, Abbruzzese JL, Li D. Dong X, et al. Oncologist. 2011;16(1):61-70. doi: 10.1634/theoncologist.2010-0127. Epub 2011 Jan 6. Oncologist. 2011. PMID: 21212431 Free PMC article.
High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.
Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, Shah N, Popat U, Jones RB, Andersson BS, Gulbis A, Ahmed S, Bashir Q, Parmar S, Patel K, Myers A, Rondon G, Orlowski RZ, Champlin R, Qazilbash M. Nieto Y, et al. Lancet Haematol. 2017 Jun;4(6):e283-e292. doi: 10.1016/S2352-3026(17)30080-7. Epub 2017 May 15. Lancet Haematol. 2017. PMID: 28522110 Free PMC article. Clinical Trial.
Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.
Joerger M, Burgers JA, Baas P, Doodeman VD, Smits PH, Jansen RS, Vainchtein LD, Rosing H, Huitema AD, Beijnen JH, Schellens JH. Joerger M, et al. Cancer Chemother Pharmacol. 2012 Jan;69(1):25-33. doi: 10.1007/s00280-011-1670-4. Epub 2011 May 18. Cancer Chemother Pharmacol. 2012. PMID: 21590444
79 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback